Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.

Rotta Research Laboratorium, Monza (MI), Italy.
European Journal of Pharmacology (Impact Factor: 2.68). 04/1999; 369(1):81-90. DOI: 10.1016/S0014-2999(99)00069-2
Source: PubMed

ABSTRACT The antigastrinic, antisecretory and antiulcer activities of CR 2945, (R)-1-naphthalenepropanoic acid,beta-[2-[[2-(8-azaspiro[4.5]dec-8-yl-carbonyl)-4,6-dimethylph enyl] amino]-2-oxoethyl], were investigated in vitro and in vivo in rats and cats. Its activities were compared with those of two gastrin/CCK(B) receptor antagonists, L-365,260 (3R(+)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin -3-yl)-N'-(3-methylphenyl)urea and CAM-1028 (4-[[2-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[[[1,7,7-trimethylbicyclo [2.2.1]hept-2-yl)oxy]carbonyl]amino]propyl]amino]-1-phenylethyl]amino -4-oxo-[1S-1alpha,2beta[S'(S')4alpha]]-butanoate -N-methyl-D-glucamine), of the histamine H2 receptor antagonist, ranitidine, and the proton pump inhibitor, omeprazole. Cytosolic Ca2+ elevation in rabbit parietal cells induced by gastrin (50 nM) was blocked by CR 2945 with an IC50 value of 5.9 nM. CAM-1028 and L-365,260 showed similar activity. CR 2945 antagonized pentagastrin-stimulated gastric acid secretion in rats (ED50 = 1.3 mg kg(-1) i.v. and 2.7 mg kg(-1) i.d.) and cats (1.6 mg kg(-1) i.v.). CR 2945 was slightly less potent than the reference compounds after i.v. administration, whereas after intraduodenal (i.d.) administration, it was more potent than both ranitidine and omeprazole. In the rat, the gastrin antagonism exhibited by CR 2945 was reversible and competitive, with a pA2 value of 7.33. CR 2945 had specific antigastrin activity, as it was unable to antagonize the gastric acid secretion stimulated by histamine or carbachol in rats up to the dose of 30 mg kg(-1). CR 2945 was about as efficacious as ranitidine against the indomethacin- and ethanol-induced gastric ulcers and the cysteamine-induced duodenal ulcer in rats. On the contrary, L-365,260 was only slightly effective. These results suggest that CR 2945 might be a promising compound for the therapy of acid-related disorders, and that its clinical use could help clarify the therapeutic potential of gastrin/CCK(B) receptor antagonists in the gut.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cholecystokinin (CCK) is a hormone secreted by the I-cells of the upper small intestine in response to fat, protein, and some nonnutrients, for example, camostat, and a peptide/neurotransmitter secreted by neurons of the central and peripheral nervous systems. There are multiple molecular forms of CCK, for example, CCK-8, CCK-33, and CCK-58, with an active site located within the first eight amino acids of the carboxyl terminus and with a sulfate group on the seventh tyrosine residue. Physiologically, CCK increases pancreatic secretions and gallbladder and smooth muscle contractions as well as inhibits gastric emptying and food intake. CCK evokes these responses by activating two G protein-coupled receptors: CCK(1) and CCK(2). CCK(1) receptors are located mainly in the alimentary tract and contain two affinity states, high and low, whereas CCK(2) receptors are found mainly in the brain. Although a CCK-mediated reduction in cumulative food intake occurs by the activation of low-affinity CCK(1) receptors located on vagal afferents, the vagus, and the splanchnic nerves are necessary for the reduction of meal size (MS) and the prolongation of the inter-meal interval (IMI) by CCK. Finally, the reduction of food intake by CCK occurs by three possible modes of action: paracrine, endocrine, and neurocrine; thus far, the data favor a paracrine mode. In addition, the gut, which is the main source of peripheral CCK, contains the first neuronal component that senses the presence of food, the enteric nervous system. The enteric nervous system may have a role in the reduction of MS and the prolongation of the IMI by CCK.
    Progress in molecular biology and translational science 01/2013; 114:277-316. DOI:10.1016/B978-0-12-386933-3.00008-X · 3.11 Impact Factor
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Benzaldehyde semicarbazone (BS) has presented positive results in several pharmacological models, including anticonvulsivant and anti-inflammatory models. The present study evaluated the preclinical toxicity (acute and subchronic), as well as the toxicokinetic and gastroprotective effects of BS against ethanol lesions. Oral doses of 300 and 2000 mg/kg were used in the preclinical acute toxicity study; 100, 200, and 300 mg/kg were used in both the subchronic toxicity evaluation and the gastric study; and 300 mg/kg was used in the toxicokinetic study. No impact from the dose of 300 mg/kg could be identified; while, one animal died at 2000 mg/kg in the acute toxicity test. In the subchronic toxicity test, changes in the biochemical parameters of the liver, as well as in the histopatological evaluation, demonstrated that BS is a hepatotoxic drug. BS proved to be effective for moderate and severe gastric lesions. In the toxicokinetics study, BS presented a low concentration and rapid plasma disappearance. Several results also indicate that BS is likely to be mostly eliminated from the liver and may well undergo a first-pass effect after oral absorption. It was impossible to estimate the noobserved-adverse-effect-levels (NOAEL) and lowest-observed-adverse-effect-levels (LOAEL) due to the presence of hepatotoxicity in all tested doses.
    Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 02/2013; 55. DOI:10.1016/j.fct.2013.01.017 · 2.61 Impact Factor